Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Forero

Showing results (91-100 of 179) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR<sup>+</sup> Advanced Breast CancerSara M Tolaney, Young-Hyuck Im, Emiliano Calvo, et al.
Blood|March 7, 2018
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomasMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Breast Cancer Research and Treatment|June 16, 2014
Recurrent read-through fusion transcripts in breast cancerKatherine E Varley, Jason Gertz, Brian S Roberts, et al.
Investigational New Drugs|August 22, 2014
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinomaNizar M Tannir, Andres Forero-Torres, Radhakrishnan Ramchandren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancerIngrid A Mayer, Vandana G Abramson, Steven J Isakoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2016
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple MyelomaNoopur S Raje, Edward A Faber, Paul G Richardson, et al.
Breast Cancer Research : BCR|November 23, 2017
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclibNusayba Bagegni, Shana Thomas, Ning Liu, et al.
Blood|February 27, 2019
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignanciesAndres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, et al.
Blood|March 5, 2004
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphomaAndres Forero, Paul L Weiden, Julie M Vose, et al.
Breast Cancer Research : BCR|March 5, 2021
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancerErica M Stringer-Reasor, Jori E May, Eva Olariu, et al.
Pageof 18

Showing results (91-100 of 179) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR<sup>+</sup> Advanced Breast CancerSara M Tolaney, Young-Hyuck Im, Emiliano Calvo, et al.
Blood|March 7, 2018
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomasMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Breast Cancer Research and Treatment|June 16, 2014
Recurrent read-through fusion transcripts in breast cancerKatherine E Varley, Jason Gertz, Brian S Roberts, et al.
Investigational New Drugs|August 22, 2014
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinomaNizar M Tannir, Andres Forero-Torres, Radhakrishnan Ramchandren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancerIngrid A Mayer, Vandana G Abramson, Steven J Isakoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2016
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple MyelomaNoopur S Raje, Edward A Faber, Paul G Richardson, et al.
Breast Cancer Research : BCR|November 23, 2017
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclibNusayba Bagegni, Shana Thomas, Ning Liu, et al.
Blood|February 27, 2019
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignanciesAndres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, et al.
Blood|March 5, 2004
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphomaAndres Forero, Paul L Weiden, Julie M Vose, et al.
Breast Cancer Research : BCR|March 5, 2021
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancerErica M Stringer-Reasor, Jori E May, Eva Olariu, et al.
Pageof 18